iOnctura to Share Clinical and Preclinical Data on IOA-244 and IOA-289 at ESMO-IO in December

NEXT STORY
Global Orphan Drug Market Clinical Trials Research Insight
PREV STORY
Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cytokinetics Reports Third Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies

author_avatar
NASDAQ Market News

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

author_avatar
NASDAQ Market News